CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $78.55M, above the global median of $16.24M
- PositionProfit margin is 121.5%, higher than 95% of its Biotechnology peers (median -45.7%)
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
750.07MUSDvs all stocks (USD)
Trailing P/E
2.16xvs Biotechnology peers
Revenue (TTM)
299.77MUSDvs all stocks (USD)
Profit Margin
121.50%vs Biotechnology peers
Beta
1.13xvs all stocks
52-Week Change
106.94%vs all stocks
Market Capitalization
750.07MUSDvs all stocks (USD)
Enterprise Value
670.02MUSDvs all stocks (USD)
Trailing P/E
2.16xvs Biotechnology peers
Forward P/E
8.72xvs Biotechnology peers
PEG Ratio
-0.0813xvs Biotechnology peers
Price to Sales (TTM)
2.57xvs Biotechnology peers
Price to Book (MRQ)
1.93xvs Biotechnology peers
Enterprise to Revenue
2.23xvs Biotechnology peers
Enterprise to EBITDA
5.28xvs Biotechnology peers
Gross Margin
92.17%vs Biotechnology peers
Profit Margin
121.50%vs Biotechnology peers
Operating Margin
20.21%vs Biotechnology peers
Return on Assets (TTM)
22.88%vs Biotechnology peers
Return on Equity (TTM)
174.08%vs Biotechnology peers
Revenue (TTM)
299.77MUSDvs all stocks (USD)
Revenue per Share (TTM)
16.53USDUpdated Jul 19, 2026Quarterly Revenue Growth
10.30%vs Biotechnology peers
Gross Profit (TTM)
243.41MUSDvs all stocks (USD)
EBITDA (TTM)
131.28MUSDvs all stocks (USD)
Net Income (TTM)
364.23MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-24.40%vs Biotechnology peers
Operating Cash Flow (TTM)
79.27MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
78.55MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
294.28MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
19.62MUSDFY2025 · Dec 31, 2025Gross Profit
274.66MUSDFY2025 · Dec 31, 2025Operating Income
125.47MUSDvs all stocks (USD)
Pre-tax Income
121.83MUSDFY2025 · Dec 31, 2025Income Tax Expense
-245.20MUSDFY2025 · Dec 31, 2025Net Income
367.02MUSDFY2025 · Dec 31, 2025EBIT
129.15MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
131.56MUSDFY2025 · Dec 31, 2025Research & Development
33.30MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
115.90MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.68MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.32MUSDFY2025 · Dec 31, 2025EPS (Basic)
20.40USDFY2025 · Dec 31, 2025EPS (Diluted)
19.48USDFY2025 · Dec 31, 2025Basic Shares Outstanding
17.99MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
17.99MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
367.02MUSDFY2025 · Dec 31, 2025Operating Cash Flow
87.20MUSDFY2025 · Dec 31, 2025Free Cash Flow
87.20MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.42M of depreciation against 0 of capital expenditure, and its own free-cash-flow line reads 75.66M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.64MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.06MUSDFY2025 · Dec 31, 2025Interest Paid
6.57MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
367.02MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.42MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-245.85MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.71MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-39.98MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.15MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.85MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.82MUSDFY2025 · Dec 31, 2025Capital Expenditures
0.00USDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-153.49MUSDFY2025 · Dec 31, 2025Sale of Investments
61.13MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-92.36MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-7.50MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
-7.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
18.48MSharesUpdated Jul 19, 2026Float Shares
15.94MSharesUpdated Jul 19, 2026Shares Short
3.25MSharesUpdated Jul 19, 2026Short Ratio
8.54daysvs all stocks
Short % of Shares Outstanding
18.05%vs all stocks
% Held by Insiders
3.39%vs all stocks
% Held by Institutions
93.67%vs all stocks
Total Cash (MRQ)
146.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.93USDUpdated Jul 19, 2026Total Debt (MRQ)
45.72MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1143xvs Biotechnology peers
Current Ratio (MRQ)
2.62xvs Biotechnology peers
Book Value per Share (MRQ)
21.64USDUpdated Jul 19, 2026Total Assets
513.59MUSDvs all stocks (USD)
Total Current Assets
240.17MUSDFY2025 · Dec 31, 2025Total Liabilities
122.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
273.43MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
22.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
99.24MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
114.38MUSDFY2025 · Dec 31, 2025Accounts Receivable
51.76MUSDFY2025 · Dec 31, 2025Inventory
11.51MUSDFY2025 · Dec 31, 2025Accounts Payable
7.19MUSDFY2025 · Dec 31, 2025Short-term Debt
30.43MUSDFY2025 · Dec 31, 2025Deferred Revenue
29.07MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt
22.88MUSDFY2025 · Dec 31, 2025Common Stock (Book)
18.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.02BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
391.48MUSDvs all stocks (USD)
52-Week Low
18.80USDUpdated Jul 19, 202652-Week High
52.24USDUpdated Jul 19, 202652-Week Change
106.94%vs all stocks
Beta
1.13xvs all stocks
50-Day MA
33.48USDUpdated Jul 19, 2026200-Day MA
34.43USDUpdated Jul 19, 2026Avg 10-Day Volume
414.19KSharesUpdated Jul 19, 2026Avg 30-Day Volume
388.01KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
19.29USDUpdated Jul 19, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 121.5%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 1.22Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 174.1%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 1.74Industry median: -0.22Industry P95: 0.23Peers compared: 261
Return on assets is 22.9%, higher than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: 0.23Industry median: -0.20Industry P95: 0.15Peers compared: 261
P/E ratio is 2.16×, lower than 95% of its Biotechnology peers (median 32.39×)Notable
P/E ratio: 2.16Industry median: 32.39Industry P5: 5.49Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 364,232,000Operating Cash Flow (USD, TTM): 79,273,000
Financial Health
Altman Z-Score 2.63: safe zoneNotable
Altman Z-Score: 2.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $78.55M, above the global median of $16.24MNotable
Levered free cash flow (USD): 78,553,752Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bright Minds Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Candel Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zevra Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Lianhuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhuzhou Qianjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sanyou Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oculis Holding AG
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sk Biopharmaceuticals Co., Ltd.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
XD Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated
Games Workshop Group PLC
9 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios Elevated